Search Follow us

 

Over 2017 BiondVax crystallised its late-stage development plans for lead asset M-001, a potentially universal influenza vaccine. Following its discussions with the regulatory authorities and gaining access to new capital (European Investment Bank and share issues), the company confirmed on 27 December 2017 that it will initiate a pivotal Phase III trial on its own for a universal flu vaccine indication (likely to start in Q318). We have revised our assumptions substantially and increased our valuation to $200m (NIS689m) or $32.4/ADS (NIS2.80/share) from $165m previously.

Continue reading

This version is programmatically created by Responsive Labs and qualified in its entirety to the original PDF.

Powered by Responsive Labs